Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 1:14 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1849–1872 of 54,972 matching trials from the live ClinicalTrials.gov search.
Conditions
Arrhythmogenic Cardiomyopathy, PKP2-ACM, PKP2-ARVC
Interventions
Not listed
Lead sponsor
Lexeo Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
6
States / cities
Redwood City, California • Baltimore, Maryland • Columbia, Maryland + 3 more
Conditions
Solid Tumor, Adult, Mesothelioma, NSCLC
Interventions
VT3989, Nivolumab & Ipilimumab, Osimertinib, Pemetrexed/Carboplatin
Drug
Lead sponsor
Vivace Therapeutics, Inc
Industry
Eligibility
18 Years and older
Enrollment
434 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
9
States / cities
San Francisco, California • Chicago, Illinois • Boston, Massachusetts + 5 more
Conditions
IBS - Irritable Bowel Syndrome
Interventions
Psilocybin 25 mg, Psychotherapy Treatment Session, Niacin 100 mg
Drug · Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
New York, New York
Conditions
Anaplastic Large Cell Lymphoma, Recurrent Childhood Anaplastic Large Cell Lymphoma
Interventions
monoclonal antibody SGN-30, therapeutic hydrocortisone, ifosfamide, carboplatin, etoposide, methotrexate, cytarabine, pharmacological study, laboratory biomarker analysis
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 21 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Hyperglycemia in Pregnant Diabetic Patients
Interventions
insulin pre-treatment
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Minneapolis, Minnesota
Completed Not applicable Interventional Accepts healthy volunteers

Tailored Messaging for CRC Screening

NCT03310892
Conditions
Colorectal Cancer
Interventions
Generic message, Tailored message
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
50 Years to 75 Years
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Myelodysplastic Syndromes
Interventions
Total Body Irradiation, Fludarabine, Campath 1H
Radiation · Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Not listed
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
2
States / cities
Houston, Texas
Conditions
Lung Cancer
Interventions
carboplatin, cisplatin, irinotecan hydrochloride, paclitaxel, neoadjuvant therapy, surgical procedure, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2004
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Lupus Erythematosus, Systemic
Interventions
epratuzumab
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
3
States / cities
New York, New York • Pittsburgh, Pennsylvania • Charleston, South Carolina
Withdrawn Early Phase 1 Interventional

S-Nitrosylation Therapy of COVID-19

NCT04528771
Conditions
SARS-CoV2 Infection, Covid19
Interventions
SNO, Nitrogen gas
Drug
Lead sponsor
James Reynolds
Other
Eligibility
18 Years to 89 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Pain
Interventions
Ziconotide
Drug
Lead sponsor
Elan Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
65
States / cities
Huntsville, Alabama • Sun City West, Arizona • Tucson, Arizona + 58 more
Conditions
Fall Injury, Fall Patients, Mobility Limitation
Interventions
FAST Program, Otago Exercise Program
Other
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
65 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Kansas City, Kansas
Conditions
Obesity
Interventions
RGT001-075, Placebo
Drug
Lead sponsor
Regor Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
10
States / cities
Los Angeles, California • Valparaiso, Indiana • Omaha, Nebraska + 7 more
Conditions
Myelofibrosis, Polycythemia Vera, Thrombocytosis
Interventions
Ruxolitinib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
2
States / cities
Rochester, Minnesota • Houston, Texas
Conditions
Low Back Pain
Interventions
Tanezumab 20 mg IV, Placebo for naproxen, Tanezumab 10 mg IV, Tanezumab 5 mg IV, Placebo for tanezumab, Naproxen
Biological · Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,359 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
135
States / cities
Anniston, Alabama • Birmingham, Alabama • Hueytown, Alabama + 101 more
Conditions
Lung Cancer, Prostate Cancer, Neoplasm Metastasis, Bone Cancer
Interventions
Enbrel
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
San Antonio, Texas
Conditions
Rheumatoid Arthritis
Interventions
MLTA3698A, adalimumab, leflunomide, methotrexate, placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
14
States / cities
Anniston, Alabama • Birmingham, Alabama • Peoria, Arizona + 11 more
Conditions
Hypertrophic Cardiomyopathy
Interventions
Not listed
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
16 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Patient Satisfaction, Pulmonary Rehabilitation
Interventions
TrachPhone Heat Moisture Exchange, Trach Collar
Device
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Tampa, Florida
Conditions
Dual Energy CT (DECT), Prostate Cancer
Interventions
Dual Energy Computed Tomography
Diagnostic Test
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Male only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Metastatic Breast Cancer
Interventions
Approved therapy will be assigned based on molecular profile and RPMA results
Drug
Lead sponsor
Translational Drug Development
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
3
States / cities
Scottsdale, Arizona • Fairfax, Virginia • Spokane, Washington
Conditions
Constipation, DMD
Interventions
SmartPill ingestion
Device
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
18 Years and older · Male only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Fabry Disease
Interventions
DRX005B
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Completed No phase listed Observational

Retrospective Modulus ALIF Study

NCT05566704
Conditions
Degenerative Disc Disease, Spondylolisthesis, Stenosis
Interventions
Modulus ALIF System
Device
Lead sponsor
NuVasive
Industry
Eligibility
18 Years and older
Enrollment
123 participants
Timeline
2022 – 2024
U.S. locations
5
States / cities
Orange, California • San Diego, California • Atlanta, Georgia + 2 more